Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 88

1.

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.

Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ.

J Am Coll Cardiol. 2017 Aug 8;70(6):704-712. doi: 10.1016/j.jacc.2017.06.016. Epub 2017 Jun 12.

2.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group.

N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.

3.

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*.

Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18.

4.
5.

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.

Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, Erondu N.

Diabetes Care. 2017 May;40(5):632-639. doi: 10.2337/dc16-2427. Epub 2017 Mar 13.

PMID:
28289041
6.
7.

Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.

de Winter W, Dunne A, de Trixhe XW, Devineni D, Hsu CH, Pinheiro J, Polidori D.

Br J Clin Pharmacol. 2017 May;83(5):1072-1081. doi: 10.1111/bcp.13180. Epub 2017 Jan 31.

PMID:
28138980
8.

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.

Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, Erondu N, Desai M, Shaw W, Vercruysse F, Yee J, Deng H, de Zeeuw D; CANVAS-R Trial Collaborative Group.

Diabetes Obes Metab. 2017 Mar;19(3):387-393. doi: 10.1111/dom.12829. Epub 2017 Jan 25.

9.

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.

Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, Arakawa K, Togo M, Inagaki N, Kaku K.

Adv Ther. 2017 Feb;34(2):436-451. doi: 10.1007/s12325-016-0457-8. Epub 2016 Dec 15.

10.

The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.

Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, Alba M.

Diabetes Care. 2017 Feb;40(2):171-180. doi: 10.2337/dc16-1353. Epub 2016 Nov 29.

PMID:
27899497
11.

How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake.

Polidori D, Sanghvi A, Seeley RJ, Hall KD.

Obesity (Silver Spring). 2016 Nov;24(11):2289-2295. doi: 10.1002/oby.21653.

12.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.

John M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, Canovatchel W, Hamilton G.

Int J Clin Pract. 2016 Sep;70(9):775-85. doi: 10.1111/ijcp.12868.

13.

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.

Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V.

J Am Soc Nephrol. 2017 Jan;28(1):368-375. doi: 10.1681/ASN.2016030278. Epub 2016 Aug 18.

14.

Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.

Schernthaner G, Lavalle-González FJ, Davidson JA, Jodon H, Vijapurkar U, Qiu R, Canovatchel W.

Postgrad Med. 2016 Nov;128(8):725-730. Epub 2016 Jul 26.

PMID:
27391951
15.

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.

Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H.

Cardiovasc Diabetol. 2016 Jun 18;15:89. doi: 10.1186/s12933-016-0407-4.

16.

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.

Rodbard HW, Seufert J, Aggarwal N, Cao A, Fung A, Pfeifer M, Alba M.

Diabetes Obes Metab. 2016 Aug;18(8):812-9. doi: 10.1111/dom.12684. Epub 2016 Jun 7.

17.

Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.

Devineni D, Murphy J, Wang SS, Stieltjes H, Rothenberg P, Scheers E, Mamidi RN.

Clin Pharmacol Drug Dev. 2015 Jul;4(4):295-304. doi: 10.1002/cpdd.162. Epub 2014 Dec 11.

PMID:
27136910
18.

Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.

Devineni D, Manitpisitkul P, Murphy J, Stieltjes H, Ariyawansa J, Di Prospero NA, Rothenberg P.

Clin Pharmacol Drug Dev. 2015 Jul;4(4):279-86. doi: 10.1002/cpdd.151. Epub 2014 Dec 11.

PMID:
27136908
19.

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.

Tanaka A, Inoue T, Kitakaze M, Oyama J, Sata M, Taguchi I, Shimizu W, Watada H, Tomiyama H, Ako J, Sakata Y, Anzai T, Uematsu M, Suzuki M, Eguchi K, Yamashina A, Saito Y, Sato Y, Ueda S, Murohara T, Node K.

Cardiovasc Diabetol. 2016 Apr 4;15:57. doi: 10.1186/s12933-016-0381-x.

20.

Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis.

Sinclair AJ, Bode B, Harris S, Vijapurkar U, Shaw W, Desai M, Meininger G.

J Am Geriatr Soc. 2016 Mar;64(3):543-52. doi: 10.1111/jgs.14028.

Supplemental Content

Loading ...
Support Center